Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Kineta is a biotechnology company focused on developing next-generation immunotherapies targeting innate immunity to treat cancer. Its pipeline includes monoclonal antibodies like KVA12123, a VISTA blocker, and anti-CD27 agonists, aimed at overcoming tumor immune resistance. The company targets solid tumors such as NSCLC, CRC, OC, RCC, and HNSCC, offering potential transformative treatments in the immuno-oncology market.
This description was generated via AI from an annual report. Updated about 1 year ago.